Home » Stocks » BTAI

BioXcel Therapeutics, Inc. (BTAI)

Stock Price: $45.69 USD -1.36 (-2.89%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $46.90 +1.21 (2.65%) Oct 30, 6:24 PM

Stock Price Chart

Key Info

Market Cap 1.02B
Revenue (ttm) n/a
Net Income (ttm) -53.62M
Shares Out 22.35M
EPS (ttm) -2.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $45.69
Previous Close $47.05
Change ($) -1.36
Change (%) -2.89%
Day's Open 47.29
Day's Range 44.28 - 47.44
Day's Volume 317,733
52-Week Range 3.76 - 71.50

More Stats

Market Cap 1.02B
Enterprise Value 956.81M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.35M
Float 12.66M
EPS (basic) -2.87
EPS (diluted) -2.94
FCF / Share -2.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.69M
Short Ratio 4.62
Short % of Float 21.27%
Beta 1.63
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 19.03
Revenue n/a
Operating Income -53.98M
Net Income -53.62M
Free Cash Flow -42.66M
Net Cash 64.59M
Net Cash / Share 2.89
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -64.42%
ROE -136.53%
ROIC 931.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(140.75% upside)
Current: $45.69
Target: 110.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-33.60-19.96-4.54-2.12
Net Income-32.97-19.27-4.54-2.12
Shares Outstanding16.2914.579.699.48
Earnings Per Share-2.02-1.32-0.47-0.22
Operating Cash Flow-27.28-13.51-2.20-1.29
Capital Expenditures-0.87-0.34--
Free Cash Flow-28.15-13.85-2.20-1.30
Cash & Equivalents32.4342.570.89-
Total Debt1.03-0.37-
Net Cash / Debt31.4042.570.52-
Book Value26.9038.89-0.98-0.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioXcel Therapeutics, Inc.
Country United States
Employees 31
CEO Vimal D. Mehta

Stock Information

Ticker Symbol BTAI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BTAI
IPO Date March 8, 2018


BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.